Asked by: Jonathan Reynolds (Labour (Co-op) - Stalybridge and Hyde)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, how many people have been asked to self-isolate by the NHS Test and Trace app since its launch.
Answered by Helen Whately - Shadow Secretary of State for Work and Pensions
Work is underway to establish what information can be published about app usage and its role in the COVID-19 response, including information related to self-isolation taking in to account that users of the app are anonymous.
Asked by: Jonathan Reynolds (Labour (Co-op) - Stalybridge and Hyde)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the GP-to-patient ratio for female patients between 15 and 45 with epilepsy in Stalybridge and Hyde constituency.
Answered by Jo Churchill
Data on the general practitioner (GP) to patient ratio for female patients between the ages of 15 to 45 years old with epilepsy is not available at national or regional levels.
Asked by: Jonathan Reynolds (Labour (Co-op) - Stalybridge and Hyde)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what proportion of patients of child and adult mental health services administered by the NHS have (a) fetal valproate spectrum disorder, (b) fetal valproate syndrome, (c) fetal anti-convulsant syndrome and (d) autistic spectrum disorder primarily caused by valproate in pregnancy.
Answered by Nadine Dorries
We are not able to provide this information as data is not held on all patients with fetal valproate spectrum disorder, fetal valproate syndrome, fetal anti-convulsant syndrome and autistic spectrum disorder.
Asked by: Jonathan Reynolds (Labour (Co-op) - Stalybridge and Hyde)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the time taken for his Department to investigate the effects of valproate in pregnancy; and whether he plans to launch an independent review of that matter.
Answered by Nadine Dorries
The report of the Independent Medicines and Medical Devices Safety Review was published on 8 July and one of the interventions it considered was sodium valproate. The Government has received the report and is carefully considering its recommendations. An update will be provided in due course.
The Medicines and Healthcare products Regulatory Agency (MHRA) is developing a valproate registry, which aims to monitor the use of valproate in girls and women in the United Kingdom, and to identify and monitor outcomes in any children born to women on valproate as well as ensuring compliance with the current regulatory requirements. There has been a gradual decline in prescribing of valproate to women of childbearing age over several years, and the MHRA is working with the National Health Service and professional regulators to ensure that women with epilepsy receive the healthcare they require.
Asked by: Jonathan Reynolds (Labour (Co-op) - Stalybridge and Hyde)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what estimate he has made of the cost to the public purse of providing social care for children diagnosed with fetal valproate spectrum disorder as a result of their mother being prescribed valproate in pregnancy in the last year for which data is available.
Answered by Nadine Dorries
The Department does not hold data on the cost of providing social care to children diagnosed with fetal valproate spectrum disorder.
The Department for Education is responsible for the legal and policy frameworks within which children’s social care services operate. The Ministry of Housing, Communities and Local Government provides funding to local authorities for children’s services.
Asked by: Jonathan Reynolds (Labour (Co-op) - Stalybridge and Hyde)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps he is taking to tackle delays in approval by NICE for the use of innovative cancer drugs on the NHS.
Answered by Jo Churchill
New arrangements for the assessment and adoption of new cancer drugs were introduced in 2016 to help improve patient access to new cancer drugs, including through the Government established Cancer Drugs Fund.
The National Institute for Health and Care Excellence is now committed to publishing final guidance within 90 days of a new cancer drug receiving its licence and aims to publish its draft recommendation before a licence is granted. The forecasted mean time from a new cancer drug receiving its licence to published final guidance in 2020/21 is now 1.5 months which is a reduction of 13.5 months from 2012/13. The speed of appraisal output is affected by appeals, late referrals, additional committee meetings and companies negotiating revised timing of appraisals.
Asked by: Jonathan Reynolds (Labour (Co-op) - Stalybridge and Hyde)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will issue guidance on the duties of (a) statutory health providers and (b) local authorities in meeting the care needs of adults with autism.
Answered by Caroline Dinenage
The Autism Act 2009 places a duty on the Secretary of
State for Health and Social Care to publish a strategy for meeting the needs of
autistic adults in England, and to review it periodically.
In April 2014, the cross-Government adult autism strategy,
‘Think Autism’, was published. Statutory guidance for local authorities and National
Health Service organisations was published in March 2015 to support the adult
autism strategy’s implementation.
We are currently reviewing the cross-Government autism
strategy and extending it to include children and young people. The Government
expects to publish the revised all age autism strategy by the end of the
calendar year.